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24.2+1.1 min at perfusate pH 7.06 and 6.78, respectively.
These studies indicate that the rat liver clears unbound IRS from the perfusate by a first-order kinetic process that is (a) unsaturable at pharmacologic concentrations, (b) temperature-sensitive and, to a lesser extent, influenced by lowered pH, and (c) not affected by insulin and glucagon. The liver would appear to play an important role in the metabolism of the 1,600 mol wt form of somatostatin. Clearance of endogenous IRS by the liver should be considered in the interpretation of IRS concentrations in the peripheral systemic veins.
INTRODUCTION
Concentrations of immunoreactive somatostatin (IRS)' in serum or plasma from man (1) and animals (2) (3) (4) (5) (6) (7) are higher in the hepatic portal vein or its major tributaries than in simultaneous samples drawn from the hepatic or peripheral systemic veins. Although the absolute concentrations ofIRS are lower ifthe sample is extracted before the assay (-20-600 pg/ml) (1, 2, 4) than not (-300-2,000 pg/ml) (3, 5) , the values suggest that hepatic extraction of IRS might accouint for the negative transhepatic gradients that have also been shown previously for insulin (8) and glucagon (9, 10) . However, definitive proof of IRS uptake requires measurements of total hepatic blood flow and transit time with careful attention to the manner and site of sainpling within the vessels (8, 9) . These factors vwere not reported in most of these studies (1-7), but were done in recent experiments in the conscious dog that confirmed hepatic extraction of IRS (11) . The demonstration of hepatic uptake in vitro would: (a) confirm in vivo sttudies, (b) indicate that the liver is an imlportant site for clearance of portal vein somatostatin derived by release from the pancreas and gut (3, 5, 12) or possibly by influx from the systemic circulation, and (c) be in keeping with our previous finding of an inhibition of glucagon-stimulated glycogenolysis in perfused rat liver at pharmacologic somatostatin concentrations (13) . No in vitro studies on hepatic metabolism of somatostatin have been published at the time of writing this report.
In the fasted dog, circulating 1,600-mol wt IRS is bound predominately to plasma proteins of 150,000-200,000 mol wt (6, 14) . A significant proportion of the total IRS can however exist in the unbound state after a meal (15) . However, there is little evidence that IRS binds to high molecular weight protein in rat plasma (4) . Also, rat portal venous plasma IRS appears to be heterogeneous, existing in approximately equal amounts of a 1,600 mol wt form which is similar to synthetic somatostatin and a bigger molecular weight form (4) .
The purpose of this study, therefore, was to determine whether synthetic cyclic somatostatin would be cleared in vitro by the isolated rat liver, perfused in situ with a plasma-free medium that would limit degradation of IRS caused by plasma itself (4, 16) . Clearance of IRS from the perfusate was found and further experiments were performed to characterize the effects of IRS concentration, temperature, pH, and pharmacologic amounts of insulin and glucagon on the clearance process.
METHODS

Materials
Somatostatin, as the synthetic cyclic form, (Bachem Inc., Torrance, Calif.) was prepared for perfusion as aliquots of 0.2, 2, 20, and 80 ,ug/ml Krebs-Henseleit bicarbonate buffer (KHB) containing 0.5% human serum albumin, fraction V (Sigma Chemical Co., St. Louis, Mo.) and stored at -20°C.
[Tyr"1] somatostatin for iodination was purchased from Bachem, Inc. The purity of somatostatin and [Tyr"] somatostatin was verified by high pressure liquid chromatography and amino acid analysis (courtesy of Drs. Desiderio and A. Kang, respectively). Crystalline pork insulin containing 0.001% glucagon (a gift from Dr. R. Chance, Eli Lilly and Company, Indianapolis, Ind.) was dissolved in a small volume of 0.01 N HCl, and diluted further with KHB-0.5% human albumin and 0.1 N NAOH to final concentration 3.6 mg/ml, pH 7. Crystalline beef-pork glucagon, containing 47 ,uU insulin/mg (a gift from Dr. R. Hoseley, Eli Lilly Laboratories) was diluted in 0.005 N HCI at a concentration of 1.4 mg/ml. The insulin and glucagon aliquots contained no detectable IRS when tested in the immunoassay (see below) and were stored at -20°C until used for perfusion within 3 d of preparation. Bovine albumin fraction V (Miles Laboratories, Inc., Elkhart, Ind.) was dialysed as a 10% solution against 10 
Animals
Liver donors were male Wistar rats, purchased from Harlan Laboratories, Indianapolis, Ind., and maintained on standard rat chow and water ad lib. The animals were deprived of food but not water for 48-50 h before killing, when the average body weight was 101 g (range 80-135) and the average postperfusion wet liver weight was 3.4 g (range 2.7-4.5 g). Rats were anesthetized for cannulation procedures with 0.1-0.2 ml sodium pentobarbital (40 mg/ml distilled water) given by i.p. injection.
Liver perfusion technique
Perfusate consisted of 3-4-wk-old human erythrocytes from outdated donor blood washed three times with 2-3 vol of chilled physiologic saline, then twice with chilled KHB 0.1% bovine albumin (17) , and finally, suspended in KHB containing 3.5% bovine albumin and 5.5 mM glucose to a hematocrit of 8% (18) . The volume of perfusate used to prime the circuit before cannulation of the liver was 135 ml in each experiment. The pH was adjusted (using a glass electrode) to 7.40 with 1 M sodium bicarbonate after equilibration in 95%: 5%, 02: CO2 for 20-30 min recirculation at 37°C, or 24-26°C as described below. The recirculating perfusion system of Hems et al. (19) that we previously used to study insulin metabolism (18) was modified by pumping (rather than delivering by a hydrostatic head of pressure) the perfusate from the oxygenator through each liver by means of an infusion pump (model 2100, Extracorporeal Medical Specialties, Inc., King of Prussia, Pa.). During cannulation of the portal vein and inferior vena cava, the flow rate was set at 1.0 ml/min. Once the cannulae were secured and the flow through the liver established (<4 min), the flow rate was increased to 8.0 ml/min, this time point being designated as the start ofperfusion. The effluent was discarded for -5 min perfusion without recirculation until the level of perfusate in the reservoir reached a predetermined 85-ml total vol within the circuit. About 50 ml perfusate was therefore used in the liver washout before recirculating perfusion began. The perfusate in the reservoir was recirculated at 55 ml/min by means of a roller-type pump (model MHRE 200, WatsonMarlow Ltd., Cornwall, England).
In several experiments, the perfusate pressure was measured between the pump and the liver by a pressure transducer (model P231D, Gould Inc., Medical Products Div., Oxnard, Calif.) connected to a physiologic recorder (Dynograph model R511A, Beckman Instruments, Inc., Shiller Park, Ill.).
In preliminary experiments to test metabolic function (lactate gluconeogenesis [19] ) of livers perfused under these conditions with glucose-free perfusate at 37°C and pH 7.40, neutral lactate (1,200 ,umol) was added 28 min after the start of perfusion and glucose samples (0.4 ml) were collected from the reservoir at 30 min and every 15 min thereafter for 1 h. Lactate was not added in control studies. At the end of these, and all subsequent perfusions (see below), samples of influx and effluent were collected for blood-gas analyses.
Protocol for somatostatin perfusions Perfusion at 37°C, pH 7.40. Aliqluots of somatostatin (see Methods) were added 30 min after the start of perfusion, thereby allowing a 25-min equilibration period with recirculating perfusate. In certain experiments, insulin, -5.0 mg per perfusion or glucagon 1.4 mg per perfusion (see Methods) were added 5 min before somatostatin to obtain, at the time of somatostatin addition, estimated levels of 10 ,tM for insulin and 5 ,M for glucagon. Samples (0.8 ml) for IRS assay were removed from the reservoir 1 min before and for 1 h after addition of somatostatin at the times designated in the figures and tables.
To exclude the presence of IRS-degrading material in the perfusate during liver perfusion with low concentrations (0.2 Ag bolus) of IRS, 1 ml medium remaining at the end of perfusion was incubated in duplicate in test tubes for 1 h with -1 ng fresh somatostatin at 370 and 4°C, to act as a control. For comparison, in some perfusions, 0.16 ,ug somatostatin was added back to the recirculating medium after 1 h of liver perfuision but with the liver removed; in others, somatostatin was added to fresh perfusate circulating under identical conditions in the circuit without the liver. After perfusion of livers with higher concentrations of IRS, 1 ml aliquots of remaining perfusate were incubated at 40 and 37°C for 1 h without addition of somatostatiin to the test tubes.
To exclude binding of IRS to albumin, 80 ml of KHB containing bovine albumin 3.5 g/100 ml, 5.5 mM glucose and 9,300 pg IRS/ml was recirculated at 37°C, pH 7.44 without the liver in the system. After 1 h, 1 ml of medium was applied to a glass-jacketed 29.5 x 2.5 cm Sephadex G-25 (f) column precoated with bovine albumin and equilibrated and eluted at 37°C with 0.1 M sodium phosphate, 0.15 M sodium chloride-0.1% sodium azide, pH 7.4, at a flow rate of 0.5 ml/min. The void volume (62 ml) was marked with dextran blue and fractions (5 ml) were monitored for protein by absorbance at 280 nm and assayed for IRS. Perfusion at liver temperature of 250 and 16°C. Livers were cannulated and perfused with medium at 24-26°C before recirculation was established. Water from a temperature-controlled water bath was then pumped through a glass jacket surrounding the oxygenator to produce reservoir perfusate temperatuires of 230 or 1)°C that correspondledl, respectively, to actual liver temperatures of 250 or 16°C, which were the result of heat acquired by the perfuisate en route to the liver via the pump. Liver temperature was measured directly by a temperature probe placed between the surfaces of adjacent right lobes and connected to a continuously recordiing telethermiiomiieter (model 43 TD, Yellow Sprilngs Instrument Co., Yellow Springs, Ohio). Liver temperatures were stable for 15 min before and 1 h after addition of somatostatin 30 min from the start of perfusion.
Perfusion at lowered pH at 37°C. While being equilibrated with the gas mixture at 37°C, the perfusate pH was reduced with 1 N HCI to 7.10 or 6.80, recorded by means of a glass electrode inserted into the reservoir and connected to a digital readout pH meter calibrated with pH standard solution at 37°C. Livers were perfused at these respective perfusate pH values. Once recirculating perfusion began, the pH of the reservoir medium was monitored at 5-10-min intervals and, because of an initial increase in pH, was adjusted back to -7.10 or 6.80 with small volumes of 1 N HCI. The desired pH was reached 10 min before somatostatin was added. Recordings of pH with appropriate adjustments were made thereafter at about 15-min intervals and were averaged. The pH values shown in Table II were the means of these averages. Control incubations at 37°and 4°C in test tubes containing 1 ml medium remaining after perfusion supplemented with 1 ng somatostatin were also performed.
Analyses
Samples were kept on ice until centrifuged, supernatant fluids were stored at -20°C and assayed as IRS in <1 10o while concentrations were stable. IRS was measured in triplicate, (20) . This was observed by others with an antiserum directed towards the central portion of soIllatostatinl (22) . [1251-Tvri l] somatostatin also gave a greater sensitivity (detection limit 10.0 pg/tube or 100 pg/ml perfusate versus 14.3 pg/tube previously reported [21] ). Standards like the perfusion samples were prepared in KHB-3.5% bovine albumin -5.5 mM glucose and gave virtually identical displacement curves compared to the standards in conventional buffer (20) . The intra-assay coefficient of variation was 8.0% (n = 3). The interassay coefficients of variation in nine consecutive assays were 17 and 19%, respectively, for two internal standards with mean values of 267 and 1,786 pg/ml. Glucose was measured by the glucose oxidase method, using the Auto-Analyzer (Beckman Instrumenits Inc., Spinco Div., Palo Alto, Calif.). Blood gas analyses were performed with an automatic analyzer (model 175, Corning Medical, Corning Glass Works, Medfield, Mass.). In the experiments with insulin and glucagon, aliquots of perfusate were diluted appropriately with the immunoassay buffers and hormone measurements were made by immunoassay for insulin (23) and glucagon (24) .
Calculatiotis
IRS clearance, expressed as milliliter per minute was calculated according to the formula (25): 2.3 x v/At x log[Cl -Cx/C2 -Cx]. Cl was the initial (5 min) IRS concentrationi, C2 the final IRS conicenitration, t, the time interval betweeni Cl anid C2 mieasurements, and( Cx the asymllptote approached by C after prolonged perfusioni. Cx wvas taken as 0 as IRS levels fell below the detection limit of the assay in initial experiments extended for 90 min after addition of low doses of somatostatin. The perfusate volume (V) was calculated from the volume of samples removed and the residual volume pumped out of the circuit plus -1 ml left behind. V was assumed to remain constant because sampling accounted for about 8% vol loss. Although measured in the erythrocyte-free supernatant fluid, IRS was assumed to be cleared from the whole medium since the hematocrit was 8%. Use of the clearance formula requires that IRS is removed from the medium at a rate that obeys first-order kinetics (25) . Therefore, the formula was applied after demonstrating that semi-logarithmic plots of IRS concentration versus time for individual experiments were linear using regression analysis by the least-squares method in a Wang Computer (model WCS 20, Wang Laboratories, Inc., Lowell, Mass.). Clearances were corrected per gram postperfusion wet weight of liver. The formula, hepatic clearance (milliliter per minute per gram) divided by liver flow rate (milliliter per minute per gram) was then used to estimate extraction, i.e., the extent to which the liver extracted IRS in a single passage of perfusate (25) . The average flow rate for all the experiments was 2.3 ml/min per g (range 1.8-3.0). The t1,2 (minute) of IRS was computed using the formula t,,2 = 0.693/ K, where K (per minute) was the disappearance rate constant or the value obtained for the slope of the line on the semilog plot.
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For (Table I ). The variability in bile production rate in these experiments is difficult to interpret, since small changes in bile formation may result from mechanical factors that influence bile collection. However, we have previously noted no effect of somatostatin on oxygen uptake or bile production in a nonrecirculating system (13) . Basal oxygen uptake fell to 0.58±0. 15 ,umol/min per g and bile formation to 31±7 ,ul/h per g at 25°C. At 16°C, oxygen uptake and bile formation were reduced further to 0.28±0. 13 ,umol/min per g and 12±2
,ul/h per g, respectively.
As shown in Table II Bile production also remained unchanged. The mean pressure of the influx was 6.6 mm Hg (range 5.5 to 9.0 for four experiments) both before and during low (1.7 ng/ml, n = 1) or high (20-30 ng/ml, n = 3) IRS perfusions. Perfusion pressure remained stable (5.0 and 7.0 mm Hg) before and during two IRS perfusions at 16°C. These pressures are lower than normal portal venous pressure in the rat, reported as 12-14 cm blood (26), or 9-10 mm Hg assuming the specific gravity of blood = 1 and the specific gravity of Hg = 13.6. The absence of an effect in this system differs from the prompt lowering of portal venous pressure (27) or flow (28) after somatostatin infusion in vivo.
Finally, during all studies, livers looked macroscopically intact without patchy areas to suggest malperfusion or infarction. They were not distended, and did not exude perfusate from their surfaces. Wet to dry liver weight ratios after perfusion were within a narrow range (3.27-3.68) in all the various groups of studies.
Exclusion ofIRS binding to albumin. On Sephadex (14, 15) or unextracted rat hepatic portal vein serum (3) . As shown in Fig. 1 , the concentrations fell at a curvilinear rate, which linearised on a semilogarithmic plot with a t112 of 20.0±1.3 min and a regression coefficient of -0.989±0.003 (Table I ). The latter value was significantly greater (P < 0.001) than that, -0.961 ±0.008, computed from conventional arithmetic plots. Hepatic clearance was 0.84±0.04 ml/ min per g, from which it was calculated that 36±2% of IRS was extracted from the perfusate in one transhepatic passage (Table I ). The recovery of IRS was 93.2±4.5% from the perfusate, which had been incubated for 1 h at 370C in test tubes after completion of these perfusions. By comparison and in close agreement, 91.0±1.0% of the initial IRS concentration remained 1 h after adding a fresh charge of somatostatin to the circulating medium with the liver removed (Fig. 1) . In three separate experiments, 88.0±14.5% remained after 1 h recirculation in fresh medium previously unexposed to liver (Fig. 1) . During the course of the initial viability studies as well as in these and the subsequent IRS perfusions, no visible hemolysis was observed in perfusate supernatant fluids, with the exception noted at perfusion pH 6 Effect of lowered pH on IRS clearance at 37°C. Table II shows that when the mean perfusate pH was adjusted from 7.40 to 7.06, t112 lengthened from 20.0 ±1.3 to 28.7±3.2 min, hepatic clearance fell from 0.84±0.04 to 0.54±0.08 ml/min per g, and extraction was reduced from 36±2% to 26±3%. These differences, while small, were statistically significant (see footnote to Table II) . At perfusate pH 6.78±0.02, no further changes in t1/2, hepatic clearance or extraction of IRS occurred. Recovery of IRS from media after perfusions was 90.3+4.5% at pH 7.06 and 82.3+1.5% at pH 6.78. The recoveries at pH 6.78 were significantly lower (P <0.05) than those (93.2 ± 4.5%) in studies at pH 7.40, possibly related to visible slight hemolysis in the medium. However, as shown in Table II, min, and with glucagon 17.6 and 19.4 min. Average hepatic extraction for IRS in these two groups of studies was 37% with insulin and 38% with glucagon. Both were within the normal range for extraction of IRS alone (30-42%). In these four experiments, recovery of IRS in control incubations at 37°C was 92.3±3.6%.
Because insulin and glucagon are themselves degraded by liver (29) (30) (31) , their concentrations during perfusion were measured. The average immunoreactive insulin concentration when somatostatin was added to the reservoir was 8.2 ,uM (49 ,ug/ml), and fell to 6.0 ,uM at the end of 60 min of perfusion. Likewise, the initial immunoreactive glucagon level was 2.9 ,M (10 jig/ml), and 2.0 ,uM at the end ofperfiision. Although the initial concentrations were 82 and 58% of those expected for insulin and glucagon from the estimated amounts of each hormone added, respectively, other in vitro studies with intact rat liver cell preparations suggest these concentrations were high enouigh to saturate insulin (30) ossesses a system which in a similar perfusion system (18) . Also, glucagon did nbound in the perfusate. not affect insulin clearance by perfused rat liver (18, nce for a role of the liver 35). Thus, while insulin, glucagon, and somatostatin affect each other's secretion by the pancreatic islets iperature, hepatic clear- (36) , present evidence suggests that they do not appear -r kinetics at concentra-to modify one another's clearance by intact liver measured in unextracted preparations in vitro. Ishida and co-workers (10) rec portal blood or of un-cently reported that exogenous somatostatin infusion la (14, 15) . IRS clearance modified hepatic extraction of insulin and glucagon logic IRS concentrations in the anesthetized dog. The discrepancy between their tilure to saturate hepatic observations in vivo and the results in vitro (18) might a significant amount of be due, inter alia, to species differences or to profound ium, because recovery of effects of somatostatin infusion on hepatic portal )ut the liver was >85%. venous-blood flow (10, 28) that are not observed in e insulin clearance is the isolated perfused liver system. concentrations in similar
The clearance of IRS by the liver does not appear to '), thus excluding in vitro be a nonselective type of process because other low saturability of IRS clear-molecular mass peptides that are secreted into the required to determine hepatic portal vein such as C-peptide (3,000 daltons) pacity for IRS clearance from the pancreas or heptadecapeptide gastrin (2,098 e or Kupffer-cell popula-daltons) from the stomach are not significantly extracted by perfused rat liver (37, 38) . Bovine 1-84 was less effective after parathyroid hormone, which primarily reaches the liver the liver and, to a more via the systemic arterial circulation, is specifically perfusate. This tempera-cleaved by perfused rat liver to parathyroid hormone suggests that tempera-fragments that are biologically active and resemble cesses, binding interac-those seen in the peripheral blood (39 From a teleologic viewpoint, the liver probably serves as a major site for inactivation, by degradative catabolism, of somatostatin. The liver has a strategic anatomic location between the somatostatin-rich gut and pancreas and the systemic circulation, into which the unrestricted entry of active somatostatin from the gastrointestinal tract might have excessive ubiquitous effects. Rapid hepatic clearance and catabolism could complement plasma degradation and, in certain species, a neutralizing effect of plasma protein binding as mechanisms to limit the peripheral effects of somatostatin. We have not examined hepatic degradaion of somatostatin, but it is highly likely that rather than accumulate unchanged in the liver, the peptide is ultimately cleaved into small fragments. This has been demonstrated with homogenates of brain (40) , and in blood (1, 4, 16) . Further studies on this point are needed.
The liver might also be a site of biologic action for somatostatin. Clearance of the peptide and the presence of extractable, biologically active somatostatin in rat hepatic portal vein plasma (41) would favor this role, but the evidence in favor of this notion is conflicting. Reports of inhibition by somatostatin of glucagon-stimulated glucose formation by perfused rat liver (13) and isolated hepatocytes (42) , and of cyclic AMP released by isolated rat hepatocytes (43) and liver cell plasma membranes (44) must be interpreted cautiously, because the concentrations of somatostatin were unphysiologic, i.e., 20-1,000-fold higher than IRS levels in blood. Similar effects in vitro have not been found by other investigators (45, 46) . Presently, therefore, a physiologic action for somatostatin on hepatic metabolism appears unsubstantiated, but pharmacologic effects could still occur.
The very high capacity of the liver to clear the 1,600 mol wt form of somatostatin from the hepaticportal influx has physiologic and clinical implications in the interpretation of levels as well as the effects of IRS circulating in peripheral venous blood. First, either no significant changes (1) or only relatively small increments in peripheral vein IRS have been measured in normal man (47) following nutrient stimuli that elevate markedly the IRS concentrations in the portal venous systems in animals (3, 5, 14, 15) . Preliminary evidence for the existence of a transhepatic IRS gradient in obese patients had been reported recently (1) . Second, a higher molecular weight form of IRS ("big IRS") not dissociable by 6 M urea, has been identified (4) in peripheral rat plasma as the dominant species (95%), and has also been found in a small proportion of human sera (16) . Because the 1,600 mol wt form and big IRS were found in approximately equal amounts in rat portal blood (4), it is possible that the bigger form was less susceptible to hepatic uptake and degradation and appeared more readily peripherally. In support of this possibility, 1,600 mol wt IRS was very rapidly degraded by human amniotic fluid, but the big IRS in the fluid was not degraded (48) . Similar precedents have been established for insulin, which is cleared and degraded more rapidly by the liver than proinsulin (29) . Finally, it is conceivable that in certain diseases in man, such as somatostatinoma of the pancreas, the liver may restrict or limit increased amounts of free, biologically active, 1,600 mol wt somatostatin, secreted by these tumors (49) and identified in peripheral blood (49, 50) , from entering the systemic circulation unless the primary is large and/or hepatic metastases develop (49, 50) .
In conclusion, the perfused rat liver clears IRS in its unbound state from the perfusate by a first-order kinetic process that cannot be saturated at unphysiologic concentrations (388 nM) of the peptide. Clearance is temperature-sensitive, modestly reduced by lowered pH, and not influenced by pharmacologic levels of insulin and glucagon. Further studies are required to characterize the mechanism(s) involved. Hepatic extraction of IRS released from the pancreas and gastrointestinal tract should be considered in evaluating the changes or effects of IRS in peripheral venous blood.
